Establishing bioequivalence for inhaled drugs; weighing the evidence. - Wikidata - wikimedia - TriplyDB

Establishing bioequivalence for inhaled drugs; weighing the evidence.

Establishing bioequivalence for inhaled drugs; weighing the evidence.

http://www.wikidata.org/entity/Q37893662

about

Switching treatments in COPD: implications for costs and treatment adherence Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.Pharmacokinetic studies for proving bioequivalence of orally inhaled drug products-critical issues and concepts.Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers.Switching from branded to generic inhaled medications: potential impact on asthma and COPD.Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products

P2860

Q26776324-2FB8320E-450F-472A-8396-C4721BFCE641 Q30525704-B485F3B5-47A7-4FE3-A8D9-FEAB4D593238 Q35675762-FE9FBCC3-2E78-4FE4-A0DD-179A1F64B07B Q38084738-47E2DC9E-567A-4152-AB6E-34DA2B8028D4 Q38837545-380B4354-CA80-4CC1-A3AE-288A4F2A4729 Q39176996-A7110247-E493-45EA-B70B-6EB147250A8B Q43538267-3AA59E92-ABE2-4FA3-96EA-A33137389CB5 Q58869538-6E6E3C37-504B-413B-AAB2-3008E7157F4F

P2860

Establishing bioequivalence for inhaled drugs; weighing the evidence.

http://www.wikidata.org/entity/Q37893662

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Establishing bioequivalence for inhaled drugs; weighing the evidence.

@en

Establishing bioequivalence for inhaled drugs; weighing the evidence.

@nl

type

label

Establishing bioequivalence for inhaled drugs; weighing the evidence.

@en

Establishing bioequivalence for inhaled drugs; weighing the evidence.

@nl

prefLabel

Establishing bioequivalence for inhaled drugs; weighing the evidence.

@en

Establishing bioequivalence for inhaled drugs; weighing the evidence.

@nl

P1433

Q37893662-82050331-3B20-4C86-A2B6-2D0C94046FDE

P1476

Q37893662-FFF015CA-7DF5-40AF-8433-F59CF230E3F2

P2093

Q37893662-3C0DA7FE-30FF-4F1A-85CF-15ABEFEA4B99

Q37893662-E6761763-4B61-428B-A61E-C60DAA458C1B

P2860

Q37893662-01D88E4C-BC45-4D64-83B5-256B7EA061E7

Q37893662-1C9A10D2-7EAE-43E7-A7B0-D9D2EC2E291D

Q37893662-3B2AC648-A845-4DF2-8BA2-D8BF22F3A028

Q37893662-427CB3C9-1E39-4345-9033-180DB93F04ED

Q37893662-4BB00185-E6B5-406F-9FFF-506F4084469B

Q37893662-5E246926-5DCB-4AB4-A92B-595EA6A948F5

Q37893662-5F0DD9FF-6B48-43BA-872A-A2BC97107C14

Q37893662-6EE30230-6AD3-4045-8DCE-5903C69AD290

Q37893662-6FE98204-0127-4373-8A51-9AA79F8B74BC

Q37893662-8821015B-C58F-498F-9256-FC5FBA091B51

P304

Q37893662-F33F0952-07E0-49A1-AD8E-4E6A4A9D87A3

P31

Q37893662-F6EBED9F-5008-494C-BCDD-14CDA720E72E

P356

Q37893662-E91CB1D7-C6C4-4E8B-8DC6-70AEF72741FA

P407

Q37893662-9C37B639-A620-4B67-8EF4-63F5DABD0531

P433

Q37893662-AC683843-2117-4D82-9670-3F6FB185DD89

P478

Q37893662-B601A86B-C819-4039-AA46-B36BCC42E25F

P577

Q37893662-F00F5C89-C0AD-4106-BB08-8AB722BFDBC6

P698

Q37893662-28622ED8-1505-4A66-B85D-DEE6CD11BE17

P356

17425247.2011.592827

P1433

Expert Opinion on Drug Delivery

P1476

Establishing bioequivalence for inhaled drugs; weighing the evidence.

@en

P2093

David A Parkins

http://www.w3.org/2001/XMLSchema#string

Peter T Daley-Yates

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone pr

The relationship between moisture or mould observations in houses and the state of health of their occupants.

Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer

Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method

Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung.

Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.

In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review

In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.

Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.

Standards for bioequivalence of inhaled products.

P304

1297-1308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425247.2011.592827

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21699442

http://www.w3.org/2001/XMLSchema#string